WHAT IS CLAIMED IS:

1. A stable liquid pharmaceutical formulation, comprising:

(A) an infliximab;

(B) a surfactant;

(C) one or more sugar and/or sugar derivative selected from the group consisting of sorbitol, mannitol, sucrose and trehalose; and

(D) a buffer comprising acetate or histidine.

2. The stable liquid pharmaceutical formulation of claim 1, wherein the infliximab (A) has a concentration of 10 to 200 mg/ml.

3. The stable liquid pharmaceutical formulation of claim 1 or claim 2, wherein the surfactant (B) comprises polysorbate, poloxamer, or a mixture thereof.

4. The stable liquid pharmaceutical formulation of any one of claims 1 to 3, wherein the surfactant (B) comprises polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a mixture of two or more thereof.

5. The stable liquid pharmaceutical formulation of any one of claims 1 to 3, wherein the surfactant (B) comprises polysorbate 80.

6. The stable liquid pharmaceutical formulation of any one of claims 1 to 5, wherein the surfactant (B) has a concentration of 0.02 to 0.1% (w/v).

7. The stable liquid pharmaceutical formulation of any one of claims 1 to 6, wherein the one or more sugar and/or sugar derivative selected from the group consisting of sorbitol, mannitol, sucrose and trehalose (C) has a concentration of 1 to 10% (w/v).

8. The stable liquid pharmaceutical formulation of any one of claims 1 to 7, wherein the buffer (D) comprises acetate.

9. The stable liquid pharmaceutical formulation of any one of claims 1 to 8, wherein the buffer (D) has a concentration of 1 to 50 mM.

10. The stable liquid pharmaceutical formulation of any one of claims 1 to 9, which has a pH of 4.0 to 5.5.

11. The stable liquid pharmaceutical formulation of any one of claims 1 to 10, wherein the formulation is free of aspartic acid, lysine, arginine, or mixtures thereof.

12. The stable liquid pharmaceutical formulation of any one of claims 1 to 11, wherein the formulation is free of NaCl, KCl, NaF, KBr, NaBr, Na_2SO_4, NaSCN, K_2S0_4, or mixtures thereof.

13. The stable liquid pharmaceutical formulation of any one of claims 1 to 12, which is free of a chelating agent.

14. The stable liquid pharmaceutical formulation of any one of claims 1 to 13, which has a viscosity of 0.5 cp to 10 cp after 1 month of storage at 40°C ±2C, or a viscosity of 0.5 cp to 5 cp after 6 months of storage at 5°C ±3 C.

15. A stable liquid pharmaceutical formulation, comprising:

(A) 90 to 145 mg/ml of an infliximab;

(B) 0.02 to 0.1% (w/v) of a surfactant;

(C) 1 to 10% (w/v) of one or more sugar and/or sugar derivative selected from the group consisting of sorbitol, mannitol, sucrose and trehalose; and

(D) 1 to 50 mM of a buffer comprising acetate or histidine.

16. The stable liquid pharmaceutical formulation of any one of claims 1 to 15, which is for subcutaneous administration.

17. The stable liquid pharmaceutical formulation of any one of claims 1 to 16, which is not subjected to a reconstitution step, a dilution step, or both, before use.

18. A pre-filled syringe filled with the stable liquid pharmaceutical formulation of any one of claims 1 to 15.

19. An auto-injector including the pre-filled syringe of claim 18.